Fungal infections:

Indications for SPHERUSOL:

To detect delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis.

Limitations of Use:

Use in patients with unknown exposure to C. immitis is not evaluated. Patients with acute or disseminate coccidioidomycosis, immunodeficiency and history of coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol.

Adult Dosage:

Give by intradermal inj. 18–64yrs: 0.1mL to the volar surface of forearm. Assess for induration at 48±4hrs after administration. Mean induration ≥5mm: positive for delayed-type hypersensitivity response.

Children Dosage:

<18yrs: not established.

Boxed Warning:

Larger accelerated reactions may occur. Systemic reactions; may be life-threatening or fatal. Not for IV inj.

SPHERUSOL Warnings/Precautions:

Review medical history for skin test sensitivity and related adverse reactions. Have trained personnel and medical equipment readily available. Monitor for ≥30mins post inj for adverse reactions. Immunosuppression. Infection. Elderly. Pregnancy (Cat.C). Nursing mothers.

SPHERUSOL Interactions:

Concomitant beta-blockers may antagonize epinephrine inj. Concomitant corticosteroids and immunosuppressants may suppress response to the skin test.

Adverse Reactions:

Itching, swelling, pain; anaphylactic reactions.

Generic Drug Availability:

NO

How Supplied:

Multi-dose vial (1mL)—1